Newfound Research LLC Takes Position in Becton, Dickinson and Company (NYSE:BDX)

Newfound Research LLC purchased a new stake in shares of Becton, Dickinson and Company (NYSE:BDX) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 235 shares of the medical instruments supplier’s stock, valued at approximately $58,000.

Other institutional investors have also added to or reduced their stakes in the company. Viridian Ria LLC purchased a new stake in shares of Becton, Dickinson and during the third quarter valued at $25,000. Focused Wealth Management Inc boosted its position in shares of Becton, Dickinson and by 101.7% during the third quarter. Focused Wealth Management Inc now owns 100 shares of the medical instruments supplier’s stock valued at $25,000 after buying an additional 6,000 shares during the last quarter. Penserra Capital Management LLC purchased a new stake in shares of Becton, Dickinson and during the second quarter valued at $34,000. Leelyn Smith LLC purchased a new stake in shares of Becton, Dickinson and during the second quarter valued at $34,000. Finally, Mascoma Wealth Management LLC purchased a new stake in shares of Becton, Dickinson and during the third quarter valued at $34,000. 84.25% of the stock is currently owned by institutional investors.

In other Becton, Dickinson and news, Director Rebecca W. Rimel sold 207 shares of Becton, Dickinson and stock in a transaction that occurred on Monday, August 30th. The stock was sold at an average price of $252.00, for a total value of $52,164.00. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Rebecca W. Rimel sold 244 shares of Becton, Dickinson and stock in a transaction that occurred on Thursday, September 2nd. The stock was sold at an average price of $254.00, for a total value of $61,976.00. The disclosure for this sale can be found here. Insiders have sold a total of 8,174 shares of company stock worth $2,104,313 in the last three months. 0.76% of the stock is owned by corporate insiders.

Shares of NYSE BDX traded down $2.12 during trading on Thursday, hitting $244.46. The company had a trading volume of 911,617 shares, compared to its average volume of 1,358,593. The stock has a 50 day simple moving average of $246.23 and a 200 day simple moving average of $246.88. The company has a debt-to-equity ratio of 0.72, a quick ratio of 0.90 and a current ratio of 1.33. Becton, Dickinson and Company has a 12 month low of $226.15 and a 12 month high of $267.37. The firm has a market capitalization of $70.21 billion, a P/E ratio of 35.69, a price-to-earnings-growth ratio of 2.73 and a beta of 0.70.

Becton, Dickinson and (NYSE:BDX) last posted its quarterly earnings data on Thursday, November 4th. The medical instruments supplier reported $2.59 EPS for the quarter, topping the consensus estimate of $2.45 by $0.14. Becton, Dickinson and had a return on equity of 15.97% and a net margin of 10.22%. The firm had revenue of $5.10 billion for the quarter, compared to the consensus estimate of $4.91 billion. During the same quarter last year, the company earned $2.79 earnings per share. The business’s revenue for the quarter was up 6.6% compared to the same quarter last year. As a group, analysts predict that Becton, Dickinson and Company will post 12.41 EPS for the current year.

Becton, Dickinson and declared that its board has initiated a share buyback plan on Thursday, November 4th that allows the company to buyback 10,000,000 shares. This buyback authorization allows the medical instruments supplier to buy shares of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s leadership believes its shares are undervalued.

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 31st. Investors of record on Friday, December 10th will be paid a dividend of $0.87 per share. This represents a $3.48 annualized dividend and a yield of 1.42%. The ex-dividend date is Thursday, December 9th. This is an increase from Becton, Dickinson and’s previous quarterly dividend of $0.83. Becton, Dickinson and’s dividend payout ratio (DPR) is 48.47%.

Several research firms recently commented on BDX. JPMorgan Chase & Co. cut Becton, Dickinson and from an “overweight” rating to a “neutral” rating and dropped their price objective for the company from $276.93 to $265.00 in a research report on Friday, August 6th. SVB Leerink reissued a “market perform” rating on shares of Becton, Dickinson and in a research report on Friday, October 22nd. Finally, Zacks Investment Research raised Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $250.00 target price on the stock in a research report on Tuesday, October 19th. Five research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $271.00.

Becton, Dickinson and Profile

Becton, Dickinson & Co is a medical technology company. The firm engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public.

Read More: Should I invest in “strong buy” stocks?

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.